Inovio Pharmaceuticals Inc
INO1.645USD
-0.015-0.90%
Horarios del mercado （ET）Cotizaciones retrasadas 15 min
88.13MCap. mercado
PérdidaP/E TTM
Más Datos de Inovio Pharmaceuticals Inc Compañía
Inovio Pharmaceuticals, Inc. is a biotechnology company focused on developing and commercializing deoxyribonucleic acid (DNA) medicines to help treat and protect people from human papillomavirus (HPV)-related diseases, cancer, and infectious diseases. Its proprietary investigational CELLECTRA devices are designed to deliver the plasmids into the body’s cells for optimal effect, without the use of chemical adjuvants, lipid nanoparticles or viral vectors. Its lead candidate is INO-3107 for the treatment of recurrent respiratory papillomatosis (RRP), a chronic, rare and debilitating disease caused by HPV-6 and HPV-11. Its DNA medicines in the pipeline include INO-3112 for the Treatment of HPV-related Oropharyngeal Squamous Cell Carcinoma, VGX-3100 for the Treatment of HPV-related Cervical HSIL, VGX-3100 for the Treatment of Anal or Perianal HSIL, INO-5401 for the Treatment of Glioblastoma Multiforme (GBM), and INO-5401 for the Prevention of Cancer for People with BRCA1/2 Mutation.
Información de Inovio Pharmaceuticals Inc
Símbolo de cotizaciónINO
Nombre de la empresaInovio Pharmaceuticals Inc
Fecha de salida a bolsaDec 08, 1998
Director ejecutivoShea (Jacqueline Elizabeth)
Número de empleados134
Tipo de seguridadOrdinary Share
Fin del año fiscalDec 08
Dirección660 W. Germantown Pike
CiudadPLYMOUTH MEETING
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísUnited States of America
Código postal19462
Teléfono18584103134
Sitio Webhttps://www.inovio.com/
Símbolo de cotizaciónINO
Fecha de salida a bolsaDec 08, 1998
Director ejecutivoShea (Jacqueline Elizabeth)
Ejecutivos de Inovio Pharmaceuticals Inc
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. David B. Weiner, Ph.D.
Dr. David B. Weiner, Ph.D.
Director
Director
86.62K
+2167.00%
Dr. Jacqueline Elizabeth Shea, Ph.D.
Dr. Jacqueline Elizabeth Shea, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
59.69K
+13135.00%
Dr. Laurent M. Humeau, Ph.D.
Dr. Laurent M. Humeau, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
32.62K
+3063.00%
Mr. Peter D. Kies
Mr. Peter D. Kies
Chief Financial Officer
Chief Financial Officer
30.63K
+2205.00%
Mr. Simon X. Benito
Mr. Simon X. Benito
Independent Chairman of the Board
Independent Chairman of the Board
12.19K
+2167.00%
Ms. Wendy L. Yarno
Ms. Wendy L. Yarno
Independent Director
Independent Director
10.51K
+2167.00%
Dr. Roger D. Dansey, M.D.
Dr. Roger D. Dansey, M.D.
Independent Director
Independent Director
8.92K
+2167.00%
Ms. Lota S. Zoth, CPA
Ms. Lota S. Zoth, CPA
Independent Director
Independent Director
8.73K
+2167.00%
Dr. Ann Calby Miller, M.D.
Dr. Ann Calby Miller, M.D.
Independent Director
Independent Director
--
--
Mr. Jay P. Shepard
Mr. Jay P. Shepard
Non-Executive Independent Vice Chairman of the Board
Non-Executive Independent Vice Chairman of the Board
--
--
Ver más
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. David B. Weiner, Ph.D.
Dr. David B. Weiner, Ph.D.
Director
Director
86.62K
+2167.00%
Dr. Jacqueline Elizabeth Shea, Ph.D.
Dr. Jacqueline Elizabeth Shea, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
59.69K
+13135.00%
Dr. Laurent M. Humeau, Ph.D.
Dr. Laurent M. Humeau, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
32.62K
+3063.00%
Mr. Peter D. Kies
Mr. Peter D. Kies
Chief Financial Officer
Chief Financial Officer
30.63K
+2205.00%
Mr. Simon X. Benito
Mr. Simon X. Benito
Independent Chairman of the Board
Independent Chairman of the Board
12.19K
+2167.00%
Ms. Wendy L. Yarno
Ms. Wendy L. Yarno
Independent Director
Independent Director
10.51K
+2167.00%
Desglose de ingresos
FY2025Q3
FY2025Q2
FY2025Q1
FY2024
FY2023
FY2022
FY2021
FY2020
FY2019
La empresa aún no ha revelado los datos relevantes.
Por regiónUSD
Nombre
Ganancia
Proporción
United States
0.00
0.00%
Por negocio
Por región
La empresa aún no ha revelado los datos relevantes.
Estadísticas de accionistas
Actualizado: sáb., 31 de ene
Actualizado: sáb., 31 de ene
Accionistas
Tipos de accionistas
Accionistas
Accionistas
Proporción
Alyeska Investment Group, L.P.
5.82%
Adage Capital Management, L.P.
4.99%
The Vanguard Group, Inc.
4.83%
Janus Henderson Investors
4.75%
Boxer Capital Management, LLC
3.35%
Otro
76.26%
Accionistas
Accionistas
Proporción
Alyeska Investment Group, L.P.
5.82%
Adage Capital Management, L.P.
4.99%
The Vanguard Group, Inc.
4.83%
Janus Henderson Investors
4.75%
Boxer Capital Management, LLC
3.35%
Otro
76.26%
Tipos de accionistas
Accionistas
Proporción
Hedge Fund
20.99%
Investment Advisor
6.82%
Investment Advisor/Hedge Fund
6.41%
Research Firm
2.27%
Individual Investor
0.42%
Venture Capital
0.31%
Bank and Trust
0.07%
Otro
62.71%
Participación institucional
Actualizado: jue., 1 de ene
Actualizado: jue., 1 de ene
Periodo del informe
Número de instituciones
Acciones mantenidas
Proporción
Cambio
2025Q4
278
25.33M
36.87%
+11.27M
2025Q3
283
11.15M
20.98%
-4.81M
2025Q2
303
13.60M
26.69%
-1.85M
2025Q1
358
13.94M
38.02%
-1.87M
2024Q4
376
13.66M
38.08%
+2.74M
2024Q3
379
8.99M
34.33%
-1.39M
2024Q2
391
8.36M
32.11%
+1.80M
2024Q1
412
4.61M
19.75%
-2.01M
2023Q4
431
4.68M
20.64%
-2.86M
2023Q3
449
5.16M
23.15%
-3.37M
Ver más
Actividad de los accionistas
Nombre
Acciones mantenidas
Proporción
Cambio
Cambio %
Fecha
Alyeska Investment Group, L.P.
4.00M
5.82%
+4.00M
--
Sep 30, 2025
Adage Capital Management, L.P.
3.43M
4.99%
+3.43M
--
Sep 30, 2025
The Vanguard Group, Inc.
2.71M
3.95%
+703.73K
+35.03%
Sep 30, 2025
Janus Henderson Investors
3.27M
4.75%
+3.27M
--
Sep 30, 2025
Boxer Capital Management, LLC
2.30M
3.35%
+2.30M
--
Sep 30, 2025
Millennium Management LLC
1.97M
2.87%
+1.63M
+468.67%
Sep 30, 2025
Renaissance Technologies LLC
816.34K
1.19%
+488.21K
+148.79%
Sep 30, 2025
D. E. Shaw & Co., L.P.
806.74K
1.17%
+806.74K
--
Sep 30, 2025
Morgan Stanley & Co. LLC
752.80K
1.1%
+503.85K
+202.39%
Sep 30, 2025
BofA Global Research (US)
636.06K
0.93%
-634.55K
-49.94%
Sep 30, 2025
Ver más
ETFs relacionados
Actualizado: sáb., 6 de dic
Actualizado: sáb., 6 de dic
Nombre
Proporción
iShares Micro-Cap ETF
0.02%
Invesco RAFI US 1500 Small-Mid ETF
0%
Avantis US Small Cap Equity ETF
0%
DFA Dimensional US Core Equity Market ETF
0%
iShares Russell 2000 Value ETF
0%
Global X Russell 2000 ETF
0%
Dimensional US Core Equity 1 ETF
0%
iShares Russell 2000 ETF
0%
Invesco NASDAQ Future Gen 200 ETF
0%
iShares Russell 3000 ETF
0%
Ver más
iShares Micro-Cap ETF
Proporción0.02%
Invesco RAFI US 1500 Small-Mid ETF
Proporción0%
Avantis US Small Cap Equity ETF
Proporción0%
DFA Dimensional US Core Equity Market ETF
Proporción0%
iShares Russell 2000 Value ETF
Proporción0%
Global X Russell 2000 ETF
Proporción0%
Dimensional US Core Equity 1 ETF
Proporción0%
iShares Russell 2000 ETF
Proporción0%
Invesco NASDAQ Future Gen 200 ETF
Proporción0%
iShares Russell 3000 ETF
Proporción0%
Dividendos
Un total de
0.00
USD se ha distribuido en dividendos durante los últimos 5 años.
Fecha
Dividendos
Fecha de registro
Fecha de pago
Fecha ex-dividendo
Sin datos
División de acciones
Fecha
Fecha ex-dividendo
Tipo
Relación
Jan 23, 2024
Merger
12→1
Jan 23, 2024
Merger
12→1
Jan 23, 2024
Merger
12→1
Jan 23, 2024
Merger
12→1
Fecha
Fecha ex-dividendo
Tipo
Relación
Jan 23, 2024
Merger
12→1
Jan 23, 2024
Merger
12→1
Jan 23, 2024
Merger
12→1
Jan 23, 2024
Merger
12→1
